Neoleukin Therapeutics, Inc. Gains 35.19%
Neoleukin Therapeutics, Inc. (NLTX:NASDAQ) jumped higher at $14.56, representing a gain of 35.2%. On Wed 23 Dec 20, NLTX:NASDAQ touched a New 2-Week Low of $10.77. The stock appeared on our News Catalysts scanner on Sat 19 Dec 20 at 12:20 AM in the 'INSIDER' category. From Wed 09 Dec 20, the stock recorded 60.00% Up Days and 54.55% Green Days
The share price of the company has been moving sideways in recent weeks.
About Neoleukin Therapeutics, Inc. (NLTX:NASDAQ)
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Top 10 Gainers:
- Air T, Inc. (AIRT:NASDAQ), 293.64%
- Addex Therapeutics Ltd (ADXN:NASDAQ), 93.52%
- FAT Brands Inc. (FAT:NASDAQ), 72.64%
- ID (ID:NYSEMKT), 40.92%
- Senseonics Holdings, Inc. (SENS:NYSEMKT), 40.65%
- Avinger, Inc. (AVGR:NASDAQ), 38.66%
- CSCW (CSCW:NASDAQ), 36.85%
- SIFCO Industries, Inc. (SIF:NYSEMKT), 35.9%
- Neoleukin Therapeutics, Inc. (NLTX:NASDAQ), 35.19%
- ENGlobal Corporation (ENG:NASDAQ), 29.39%